Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Overview of attention for article published in Frontiers in oncology, July 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,551 followers.

New research: Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203): Objective This study aims to assess… https://t.c

13 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.